---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002295"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:07:41.913047+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS Life Sciences prices $9.0M public offering of 12M shares and warrants at $0.75/unit

## Summary
- Gross proceeds of $9.0M from sale of 12M shares/common stock equivalents and 12M warrants at $0.75 per unit.
- Warrants exercise price $0.75 per share, immediately exercisable, expire in five years.
- A.G.P./Alliance Global Partners acting as sole placement agent; closing expected Jan 8, 2024.
- Exercise price reduced to $0.75 on ~7.5M warrants from prior issuances; term extended to Jan 8, 2029.

## SEC filing metadata
- accession: 0001104659-24-002295
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465924002295/0001104659-24-002295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465924002295/tm242414d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002295
- JSON: https://secwatch.observer/filing/0001104659-24-002295.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002295.txt

## Key facts
- Material Agreements
  SELLAS Life Sciences Group, Inc. entered into Securities Purchase Agreements with certain investors (the "Purchasers") valued at approximately $9.0 million (effective 2024-01-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors (the "Purchasers")
  - Value: approximately $9.0 million
  - Effective: 2024-01-04
  source text: On January 4, 2024, SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain investors (the “Purchasers).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465924002295/0001104659-24-002295-index.htm
- Material Agreements
  SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners (the "Placement Agent") (effective 2024-01-04).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners (the "Placement Agent")
  - Effective: 2024-01-04
  source text: On January 4, 2024, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company engaged the Placement Agent as the exclusive placement agent in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465924002295/0001104659-24-002295-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.